Ask AI

Activating the Immune Synapse in Marginal Zone Lymphoma: Clinical Integration of Emerging Bispecific Antibody Evidence

Advance your knowledge of current bispecific antibody evidence in marginal zone lymphoma to inform individualized treatment decisions through a certified ClinicalThought commentary, certified podcast, and certified text module with accompanying downloadable slides.

Share

Program Content

Activities

Rethinking MZL Therapy
Rethinking MZL: From Established Options to T-Cell–Directed Therapies
Podcast
Congratulations: You achieved a completion on 04/09/2022

Released: November 04, 2026

Expires: May 03, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.